Development of a novel RNA-based microsatellite stable predictive response signature (MSS-PRS) to identify MSS colorectal cancer (CRC) patients with a microsatellite instability-high (MSI-H) molecular phenotype

被引：0
|
作者：
Pappan, Kirk
Mayhew, Gregory
Shepherd, Jonathan
Guo, Yuelong
Beebe, Kirk
Eisner, Joel
Milburn, Michael
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-1040
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1040
引用
收藏
页数：2
相关论文
共 43 条
  • [21] Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET - a phase I, single-arm study
    Oaknin, Ana
    Gilbert, Lucy
    Tinker, Anna, V
    Brown, Jubilee
    Mathews, Cara
    Press, Joshua
    Sabatier, Renaud
    O'Malley, David M.
    Samouelian, Vanessa
    Boni, Valentina
    Duska, Linda
    Ghamande, Sharad
    Ghatage, Prafull
    Kristeleit, Rebecca
    Leath, Charles, III
    Guo, Wei
    Im, Ellie
    Zildjian, Sybil
    Han, Xinwei
    Duan, Tao
    Veneris, Jennifer
    Pothuri, Bhavana
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (01)
  • [22] Impact of BRAF-V600E mutation on immunologic characteristics of the tumor microenvironment (TME) and associated genomic alterations in patients with microsatellite instability-high (MSI-H) or mismatch-repair-deficient (dMMR) colorectal cancer (CRC)
    Salem, M.
    Kopetz, S.
    El-Refai, S.
    Tabernero, J.
    Sinicrope, F.
    Tie, J.
    George, T.
    Van Cutsem, E.
    Mauer, E.
    Lonardi, S.
    Andre, T.
    Overman, M.
    Foureau, D.
    ANNALS OF ONCOLOGY, 2022, 33 : S378 - S378
  • [23] SAFETY PROFILE OF NIVOLUMAB plus IPILIMUMAB COMBINATION THERAPY IN PATIENTS WITH DNA MISMATCH REPAIR-DEFICIENT/MICROSATELLITE INSTABILITY-HIGH (DMMR/MSI-H) METASTATIC COLORECTAL CANCER (MCRC) IN CHECKMATE-142
    Brutcher, Edith
    Khoukaz, Taline
    Hartman, Leighanne
    ONCOLOGY NURSING FORUM, 2018, 45 (02)
  • [24] Characterizing the landscape of RING-type E3 ubiquitin transferase-altered (RNF43 alt) colorectal cancer (CRC) and defining unique subsets with potential therapeutic vulnerabilities in microsatellite instability-high (MSI-H) CRC.
    Naqash, Abdul Rafeh
    Nassar, Amin
    Macera, Lisa
    Mauer, Elizabeth
    Guinney, Justin
    Chao, Calvin Y.
    Adib, Elio
    Petricoin, Emanuel
    Mittra, Arjun
    Takebe, Naoko
    Cannon, Timothy Lewis
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [25] Nivolumab in patients with DNA mismatch repairdeficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC): Long-term survival according to prior line of treatment from CheckMate-142.
    Overman, Michael J.
    Bergamo, Francesca
    McDermott, Raymond S.
    Aglietta, Massimo
    Chen, Franklin
    Gelsomino, Fabio
    Wong, Mark
    Morse, Michael
    Van Cutsem, Eric
    Hendlisz, Alain
    Neyns, Bart
    Moss, Rebecca Anne
    Zhao, Huanyu
    Cao, Z. Alexander
    Kamble, Shital
    Kopetz, Scott
    Andre, Thierry
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [26] Nivolumab plus ipilimumab combination in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC): First report of the full cohort from CheckMate-142.
    Andre, Thierry
    Lonardi, Sara
    Wong, Mark
    Lenz, Heinz-Josef
    Gelsomino, Fabio
    Aglietta, Massimo
    Morse, Michael
    Van Cutsem, Eric
    McDermott, Raymond S.
    Hill, Andrew G.
    Sawyer, Michael B.
    Hendlisz, Alain
    Neyns, Bart
    Svrcek, Magali
    Moss, Rebecca Anne
    Ledeine, Jean-Marie
    Cao, Z. Alexander
    Kamble, Shital
    Kopetz, Scott
    Overman, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [27] Nivolumab (NIVO) ± ipilimumab (IPI) in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Five-year follow-up from CheckMate 142.
    Overman, Michael J.
    Lenz, Heinz-Josef
    Andre, Thierry
    Aglietta, Massimo
    Wong, Mark Ka
    Luppi, Gabriele
    Van Cutsem, Eric
    McDermott, Raymond S.
    Hendlisz, Alain
    Cardin, Dana Backlund
    Morse, Michael
    Neyns, Bart
    Hill, Andrew Graham
    Limon, M. Luisa
    Garcia-Alfonso, Pilar
    Krishnamurthy, Anuradha
    Chen, Franklin
    Abdullaev, Sandzhar
    Soleymani, Samira
    Lonardi, Sara
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [28] Nivolumab (NIVO) plus low-dose ipilimumab (IPI) in previously treated patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Long-term follow-up.
    Overman, Michael J.
    Lonardi, Sara
    Wong, Ka Yeung Mark
    Lenz, Heinz-Josef
    Gelsomino, Fabio
    Aglietta, Massimo
    Morse, Michael
    Van Cutsem, Eric
    McDermott, Raymond S.
    Hill, Andrew G.
    Sawyer, Michael B.
    Hendlisz, Alain
    Neyns, Bart
    Svrcek, Magali
    Atasoy, Ajlan
    Zhao, Huanyu
    Lei, Ming
    Kopetz, Scott
    Andre, Thierry
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [29] Efficacy and safety of immune checkpoint inhibitors in Proficient Mismatch Repair (pMMR)/Non-Microsatellite Instability-High (non-MSI-H) metastatic colorectal cancer: a study based on 39 cohorts incorporating 1723 patients
    Wu, Qing
    Wang, Ziming
    Luo, Yang
    Xie, Xianhe
    BMC IMMUNOLOGY, 2023, 24 (01)
  • [30] Efficacy and safety of immune checkpoint inhibitors in Proficient Mismatch Repair (pMMR)/ Non-Microsatellite Instability-High (non-MSI-H) metastatic colorectal cancer: a study based on 39 cohorts incorporating 1723 patients
    Qing Wu
    Ziming Wang
    Yang Luo
    Xianhe Xie
    BMC Immunology, 24
12345